Download presentation
Presentation is loading. Please wait.
Published byLuke Ross Modified over 5 years ago
1
Nelson-Aalen plots comparing nbDMARD and TNFi cohorts for each outcome.
Nelson-Aalen plots comparing nbDMARD and TNFi cohorts for each outcome. (A) Lupus-like events; (B) Vasculitis-like events. Cumulative hazard estimates are demonstrated using Nelson-Aalen plots for each drug evaluated in the register. Infliximab appears to have the highest risk in both analyses, followed by etanercept and adalimumab. nbDMARD, non-biological disease-modifying antirheumatic drug. Meghna Jani et al. RMD Open 2017;3:e000314 Copyright © BMJ Publishing Group & EULAR. All rights reserved.
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.